Victor M. Rivera

Baylor College of Medicine — United States

Medicine · Health Sciences

57h-index15.6kcitations287works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(88), Chronic Lymphocytic Leukemia Research(77), Lung Cancer Treatments and Mutations(62), PI3K/AKT/mTOR signaling in cancer(45), Acute Lymphoblastic Leukemia research(44)

Publications287 total

Addressing multiple sclerosis disparities in Latin American and other populations
Nature Reviews Neurology·2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status
Clinical Lung Cancer·2025· 1 citedOpen Access
Hemorrhage Sites and Mitigation Strategies After Pancreaticoduodenectomy
JAMA Surgery·2024· 14 citedOpen Access
Abstract No. 595 How To Successfully Build an International Interventional Radiology Fellowship: An Update on RAD-AID International’s Sustainable Collaboration with the University of Nairobi in Kenya
Journal of Vascular and Interventional Radiology·2024Open Access
An analysis of hemorrhage after pancreaticoduodenectomy: from the gastroduodenal artery and beyond
HPB·2024Open Access
Abstract B167: Preclinical characterization of THE-349, a mutant-selective, CNS-active, fourth-generation EGFR inhibitor to overcome T790M- and C797S-mediated resistance in NSCLC
Molecular Cancer Therapeutics·2023· 2 cited
Discovery of Potent and Selective Next-Generation Pan-BCR-ABL Inhibitors for the Treatment of CML and Ph+ ALL
Blood·2023Open Access
Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing
Cell Reports Medicine·2023· 2 citedOpen Access
Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Journal of Clinical Oncology·2023· 2 cited
Data from Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
2023Open Access
Supplementary Figure Legends from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
2023Open Access
Supplementary Figures 1-6 from Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
2023Open Access
Supplementary Data from Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
2023Open Access
Data from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
2023Open Access
Data from Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models
2023Open Access
Supplementary Figure 3 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
2023Open Access
Supplementary Data from Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
2023Open Access
Supplementary Figure 1 from Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models
2023Open Access
Supplementary Table 1 from Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
2023Open Access
Supplementary Figure 2 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
2023Open Access
page 1 of 15Next →

Frequent Co-authors

Tim Clackson(27), William C. Shakespeare(11), Scott Wardwell(11), Narayana I. Narasimhan(11), Frank Wang(9), Frank G. Haluska(9), Yaoyu Ning(8), David C. Dalgarno(8), Xiaotian Zhu(7), Michael W. Deininger(7), Yihan Wang(6), Jörge E. Cortes(6), Moshe Talpaz(6), Hagop M. Kantarjian(6), Michael Gilman(6), Qurish K. Mohemmad(6), Roy M. Pollock(5), Wei‐Sheng Huang(5), James M. Wilson(5), Thomas O’Hare(4)